hydroxyurea has been researched along with Leukemia, Myelomonocytic, Acute in 9 studies
Leukemia, Myelomonocytic, Acute: A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report 2 cases of acute tumor lysis syndrome (ATLS) associated with hydroxyurea treatment." | 7.72 | Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia. ( Al-Omar, HM; Amato, D; Seki, JT; Sutton, DM, 2003) |
| "To report 2 cases of acute tumor lysis syndrome (ATLS) associated with hydroxyurea treatment." | 3.72 | Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia. ( Al-Omar, HM; Amato, D; Seki, JT; Sutton, DM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Diao, S | 1 |
| Nichols, ED | 1 |
| DiNardo, C | 1 |
| Konopleva, M | 1 |
| Ning, J | 1 |
| Qiao, W | 1 |
| Maiti, A | 1 |
| DiPippo, AJ | 1 |
| Bertolini, F | 1 |
| Cassisa, A | 1 |
| Miggiano, MC | 1 |
| Gasparin, P | 1 |
| Nand, S | 1 |
| Othus, M | 1 |
| Godwin, JE | 1 |
| Willman, CL | 1 |
| Norwood, TH | 1 |
| Howard, DS | 1 |
| Coutre, SE | 1 |
| Erba, HP | 1 |
| Appelbaum, FR | 1 |
| Seki, JT | 1 |
| Al-Omar, HM | 1 |
| Amato, D | 1 |
| Sutton, DM | 1 |
| Wei, CH | 1 |
| Yu, IT | 1 |
| Tzeng, CH | 1 |
| Fan, FS | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| Lutz, P | 1 |
| Zix-Kieffer, I | 1 |
| Souillet, G | 1 |
| Bertrand, Y | 1 |
| Dhooge, C | 1 |
| Rubie, C | 1 |
| Mazingue, F | 1 |
| Marguerite, F | 1 |
| Machinaud-Lacroix, F | 1 |
| Rialland, X | 1 |
| Plouvier, E | 1 |
| Behar, C | 1 |
| Vilmer, E | 1 |
| Philippe, N | 1 |
| Otten, J | 1 |
| Camba, L | 1 |
| Bernardi, M | 1 |
| Pescarollo, A | 1 |
| Wolff-Kormann, PG | 1 |
| Hasenfratz, BC | 1 |
| Heinrich, B | 1 |
| Kormann, B | 1 |
| Kajigaya, Y | 1 |
| Ikuta, K | 1 |
| Sasaki, H | 1 |
| Koiso, Y | 1 |
| Funabiki, T | 1 |
| Matsuyama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia[NCT00658814] | Phase 2 | 133 participants (Actual) | Interventional | 2008-12-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients surviving more than 30 days after study registration (NCT00658814)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Good Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin | 92 |
| Poor Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin | 87 |
Morphologic complete remission (CR): ANC >=1,000/mcL, platelet count >=100,000/mcL, <5% bone marrow blasts, no Auer rods, no evidence of extramedullary disease. Morphologic complete remission with incomplete blood count recovery (CRi): Same as CR but ANC may be <1,000/mcL and/or platelet count <100,000/mcL. (NCT00658814)
Timeframe: Up to 60 days
| Intervention | percentage of participants (Number) |
|---|---|
| Good Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin | 44 |
| Poor Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin | 35 |
Relapse-free survival (RFS) is defined for all patients who achieve CR or CRi. RFS is measured from the date CR or CRi is first achieved until relapse or death form any cause, with observation censored on the date of last contact for patients last known to be alive without report of relapse. Relapse from CR/CRi is defined as reappearance of leukemic blasts in the peripheral blood; or > 5% blasts in the bone marrow not attributable to another cause; or appearance or reappearance of extramedullary disease. (NCT00658814)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Good Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin | 8 |
| Poor Risk Patients: Azacitidine Plus Gemtuzumab Ozogamicin | 7 |
Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00658814)
Timeframe: Up to 5 years
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, SGPT (serum glutamic pyruvic transaminase) | AST, SGOT | Adult respiratory distress syndrome (ARDS) | Albumin, serum-low (hypoalbuminemia) | Anorexia | Bilirubin (hyperbilirubinemia) | Calcium, serum-low (hypocalcemia) | Carbon monoxide diffusion capacity (DL(co)) | Cardiac Arrhythmia-Atrial fibrilation | Cardiac General-cardiopulmonary disease | Cardiac General-Chest Pain | Cardiac troponin I (cTnI) | Cardiac-ischemia/infarction | Conduction abnormality NOS | Confusion | Constipation | Cytokine release syndrome/acute infusion reaction | Death - Disease progression NOS | Death - Multi-organ failure | Death not associated with CTCAE term - Death NOS | Dehydration | Diarrhea | Dyspnea (shortness of breath) | Edema: limb | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Glucose, serum-high (hyperglycemia) | Hemoglobin | Hemorrhage, CNS | Hemorrhage, GI - Stomach | Hemorrhage, GI - Upper GI NOS | Hemorrhage/Bleeding-platelets and red blood cells | Hepatobiliary/Pancreas-venoocclusive disease | Hypertension | Hypotension | Hypoxia | Inf (clin/microbio) w/Gr 3-4 neuts - Blood | Inf (clin/microbio) w/Gr 3-4 neuts - Catheter-rel | Inf (clin/microbio) w/Gr 3-4 neuts - Colon | Inf (clin/microbio) w/Gr 3-4 neuts - Conjunctiva | Inf (clin/microbio) w/Gr 3-4 neuts - Dental-tooth | Inf (clin/microbio) w/Gr 3-4 neuts - Kidney | Inf (clin/microbio) w/Gr 3-4 neuts - Lung | Inf (clin/microbio) w/Gr 3-4 neuts - Oral cav-gums | Inf (clin/microbio) w/Gr 3-4 neuts - Sinus | Inf (clin/microbio) w/Gr 3-4 neuts - Skin | Inf (clin/microbio) w/Gr 3-4 neuts - UTI | Inf w/normal ANC or Gr 1-2 neutrophils - Blood | Inf w/normal ANC or Gr 1-2 neutrophils - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - Skin | Infection with unknown ANC - Blood | Infection with unknown ANC - Lung (pneumonia) | Infection with unknown ANC - Skin (cellulitis) | Infection-Aspirgillosis | Infection-bacteremia | Left ventricular systolic dysfunction | Leukocytes (total WBC) | Liver dysfunction/failure (clinical) | Lymphopenia | Mood alteration - depression | Mucositis/stomatitis (functional/symp) - Oral cav | Muscle weakness, not d/t neuropathy - body/general | Neutrophils/granulocytes (ANC/AGC) | Pain - Cardiac/heart | Petechiae/purpura (hemorrhage into skin or mucosa) | Phosphate, serum-low (hypophosphatemia) | Platelets | Pleural effusion (non-malignant) | Pneumonitis/pulmonary infiltrates | Potassium, serum-low (hypokalemia) | Pulmonary/Upper Respiratory-pulmonary edema | Rash/desquamation | SVT and nodal arrhythmia - Atrial fibrillation | SVT and nodal arrhythmia - SVT tachycardia | Sodium, serum-low (hyponatremia) | Sudden death | Thrombosis/thrombus/embolism | |
| Consolidation Therapy | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 1 | 0 | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maintenance Therapy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 1 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Remission Induction Chemotherapy | 5 | 4 | 1 | 5 | 5 | 3 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 5 | 1 | 18 | 50 | 10 | 73 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 16 | 2 | 1 | 1 | 3 | 1 | 8 | 1 | 2 | 6 | 3 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 80 | 0 | 23 | 2 | 1 | 4 | 85 | 2 | 1 | 4 | 85 | 1 | 1 | 5 | 2 | 1 | 2 | 1 | 5 | 1 | 2 |
1 trial available for hydroxyurea and Leukemia, Myelomonocytic, Acute
| Article | Year |
|---|---|
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineopla | 2013 |
8 other studies available for hydroxyurea and Leukemia, Myelomonocytic, Acute
| Article | Year |
|---|---|
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, | 2021 |
Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Delayed Diagnosis; | 2017 |
Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Acute; Male; Tum | 2003 |
Trisomy 21 in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Down Syndrome; Humans; Hydroxyure | 1996 |
Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; | 1996 |
Complete haematological response with granulocyte colony stimulating factor (G-CSF) and hydroxyurea in relapsed acute myeloid leukaemia (AML) of the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Granulocyte Colony-Stimulating Factor; Humans; | 2001 |
Successful treatment with hydroxyurea of ocular involvement in chronic myelomonocytic leukemia.
Topics: Aged; Aged, 80 and over; Eye Neoplasms; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Acute; Male; | 1991 |
[Granulocyte-macrophage colony enhancing factor activity in supernatant from murine myelo-monocytic leukemia cell line (WEHI-3B)--studies of target cell using hydroxyurea suicide technic].
Topics: Animals; Cell Line; Colony-Forming Units Assay; Colony-Stimulating Factors; DNA; Granulocyte-Macroph | 1988 |